middl
east
respiratori
syndrom
coronaviru
merscov
first
emerg
saudi
arabia
march
laboratoryconfirm
case
relat
death
offici
report
world
health
organ
infect
geograph
link
saudi
arabia
travelrel
case
occur
europ
asia
dromedari
camel
suscept
merscov
infect
appear
main
reservoir
viru
howev
humantohuman
transmiss
underli
rapid
spread
merscov
within
hospit
high
seropreval
antibodi
merscov
report
dromedari
camel
middl
east
variou
countri
africa
indic
widespread
merscov
licens
vaccin
treatment
current
avail
merscov
infect
ongo
diseas
control
strategi
far
reli
minimis
contact
dromedari
camel
observ
standard
infect
control
measur
limit
nosocomi
transmiss
contact
trace
quarantin
address
unmet
need
merscov
intervent
prioritis
urgent
could
rapidli
achiev
one
health
approach
product
codevelop
use
human
prevent
diseas
camel
limit
viru
shed
block
subsequ
transmiss
human
leverag
vaccin
technolog
platform
establish
safeti
profil
target
speci
would
allow
rel
rapid
progress
product
develop
pipelin
mani
vaccin
platform
safe
evalu
human
vaccin
research
develop
camelid
infect
neglect
among
promis
human
vaccin
platform
replicationdefici
simian
adenoviru
vector
chad
boast
good
safeti
immunogen
profil
human
demonstr
clinic
trial
wide
rang
indic
includ
malaria
hiv
tuberculosi
influenza
hepat
c
ebola
one
chad
vector
term
undergon
test
dromedari
camel
show
excel
safeti
immunogen
encod
rift
valley
fever
viral
recent
made
vaccin
construct
encod
fulllength
merscov
spike
glycoprotein
genbank
access
number
target
protect
neutralis
spike
glycoprotein
transgen
sequenc
insert
region
includ
human
tissu
plasminogen
activ
signal
sequenc
nterminu
express
control
human
major
immedi
earli
cytomegaloviru
promot
includ
intron
mer
shown
elicit
hightitr
merscov
neutralis
antibodi
robust
cell
respons
spike
determin
mer
vaccin
efficaci
utilis
recent
develop
transgen
lethal
balbc
mous
model
van
doremalen
et
al
submit
express
human
dipeptidyl
peptidas
gene
locu
render
mice
suscept
merscov
infect
merscov
mous
model
uniformli
lethal
dose
higher
merscov
infect
characteris
initi
respiratori
phase
secondari
encephalit
phase
similar
describ
mer
vaccin
elicit
neutralis
antibodi
statist
signific
differ
detect
immunis
rout
mann
whitney
u
test
p
fig
merscov
neutralis
antibodi
respons
observ
among
vaccin
encod
enhanc
green
fluoresc
protein
egfp
vaccine
evalu
vaccin
efficaci
anim
challeng
intranas
day
postvaccin
merscov
strain
total
volum
observ
daili
sign
diseas
euthanasia
indic
loss
initi
bodi
weight
day
postinocul
dpi
four
anim
group
euthan
lung
collect
analys
remain
six
anim
per
group
sacrif
dpi
reach
human
endpoint
criteria
group
size
suffici
allow
detect
efficaci
mer
group
compar
control
power
use
twosampl
comparison
proport
alpha
determin
statist
softwar
egfp
vaccine
develop
sign
diseas
includ
loss
bodi
weight
ruffl
fur
lethargi
fig
weight
loss
begun
dpi
dpi
mice
egfp
group
either
succumb
infect
reach
predefin
euthanasia
criteria
fig
sign
diseas
signific
loss
bodi
weight
observ
mice
vaccin
mer
fig
c
presenc
merscov
rna
lung
brain
analys
qrtpcr
mice
n
sacrif
dpi
high
viral
load
found
lower
respiratori
tract
brain
egfpvaccin
mice
intranas
eqg
tissu
confid
interv
ci
intramuscular
eqg
tissu
ci
viral
rna
detect
mer
vaccin
mice
fig
immunohistochemistri
stain
merscov
lung
tissu
show
abund
antigen
egfpvaccin
mice
vaccin
fig
merscov
replic
observ
type
type
ii
pneumocyt
fig
insert
respiratori
cell
endotheli
cell
bronchiolar
epithelium
macrophag
egfp
control
anim
merscov
antigen
observ
dpi
brain
mice
howev
emphasi
assess
vaccin
efficaci
respiratori
phase
diseas
brain
sampl
later
peak
viru
replic
respiratori
tract
dpi
collect
address
whether
singl
dose
mer
vaccin
truli
result
steril
immun
analys
pre
post
challeng
sera
merscov
nucleoprotein
elisa
irrespect
rout
immunis
rel
low
level
igg
antibodi
nucleoprotein
detect
fig
indic
anim
like
briefli
infect
first
day
inocul
result
morbid
mortal
signific
differ
merscov
nucleoprotein
respons
detect
vaccin
group
mann
whitney
u
test
p
fig
togeth
data
provid
support
evalu
mer
vaccin
human
dromedari
camel
rel
straightforward
given
establish
safeti
profil
platform
dromedari
deploy
human
merscov
vaccin
need
safe
efficaci
atrisk
popul
includ
healthcar
worker
camel
herder
comorbid
highlight
ongo
whole
consult
ideal
target
product
profil
merscov
vaccin
howev
major
gap
remain
understand
key
immun
mechan
respons
protect
diseas
whilst
merscov
infect
elicit
high
titr
neutralis
antibodi
camel
appear
suffici
provid
longterm
protect
identif
immun
correl
protect
merscov
human
camel
allow
costeffect
diseas
surveil
vaccin
monitor
summari
demonstr
util
platform
merscov
vaccin
develop
lethal
mous
model
excel
immunogen
efficaci
observ
underpin
futur
evalu
mer
dromedari
camel
human
data
gener
analys
studi
includ
publish
articl
